TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2~* Life expectancy ≥ 3 months.~* Patients previously diagnosed with multiple myeloma~* Patients must have relapsed or relapsed and refractory multiple myeloma (MM) after at least three but not more than six prior therapeutic regimens for MM, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen.~* Patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available)~* Women must have a negative serum pregnancy test~* Voluntarily signed and dated written informed consent~Exclusion Criteria:~* Concomitant diseases/conditions~* Women who are pregnant or breast feeding.~* Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM~* Known hypersensitivity to any involved study drug or any of its formulation components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plitidepsin+Dexamethasone (Type: EXPERIMENTAL): plitidepsin + dexamethasone combination
- Dexamethasone (Type: ACTIVE_COMPARATOR): dexamethasone single agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proof of cancer~* patient is considered for treatment with capecitabine or 5-FU~* hetero- or homozygous mutant for DPYD\*2A~* able and willing to give written informed consent~* able and willing to undergo blood sampling for pharmacokinetic analysis~* life expectancy 3 months or longer~* acceptable safety laboratory values (ANC, platelet count, ASAT, ALAT, creatinine,~* WHO performance status 0-2~* no radio- or chemotherapy within the last 3 weeks prior to study entry~Exclusion Criteria:~* patients with known alcoholism, drug addiction and/or psychotic disorders that are not suitable for adequate follow-up~* women who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DPYD*2A (Type: EXPERIMENTAL): Patients are screened for a DPD-deficiency. Patients with a DPYD\*2A mutation are eligible for intervention with capecitabine/5-FU .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* Male or female~* Diagnosed with GAD according to DSM-IV~* HAMA score≥17~* Provide with written informed consent~* Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.~Exclusion Criteria:~* Serious suicidal tendency~* The score of the sixth item of HAMA ≥3~* The score of HAMD ≥21~* Pregnant or lactating women~* History of allergic or hypersensitivity to tandospirone~* Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease~* Secondary anxiety disorders~* Drug or alcohol dependence within 1 year~* Patients currently taking benzodiazepine drugs~* Drivers and dangerous machine operators~* Participated in other clinical studies in the last 30 days~* Patients with clinically significant ECG or laboratory abnormalities~* Patients with a history of epilepsy~* Patients with abnormal TSH concentration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
- Study Group (Type: EXPERIMENTAL): Comparative high dose of tandospirone treatment, 60 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children who have completed a prior phase 3 TransCon hGH trial~2. Children who have not permanently discontinued study drug in the prior trial~3. Written, signed, informed consent of the parent or legal guardian of the subject and written assent of the subject as required by the IRB/HREC/IEC~Exclusion Criteria:~1. Poorly-controlled diabetes mellitus (HbA1c ≥ 8.0%) or diabetic complications~2. Evidence of closed epiphyses, defined as bone age \> 14.0 years for females or \> 16.0 years for males~3. Major medical conditions unless approved by Medical Expert~4. Known hypersensitivity to the components of the trial medication~5. Likely to be non-compliant with respect to trial conduct (in regards to the subject and/or the parent/legal guardian/caregiver)~6. Pregnancy~7. Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- TransCon hGH (Type: EXPERIMENTAL): Once weekly subcutaneous injection of TransCon hGH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mental Health Assessment Project on the Thailand-Burma Border

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Burmese national, 18 or over, living in Thailand outside of refugee camps, meets or exceed the algorithm for the Hopkins Symptoms Checklist 25 (HSCL-25) depression subscale and/or the algorithm for the Harvard Trauma Questionnaire (HTQ) posttraumatic stress scale.~Exclusion Criteria:~* not Burmese national, under 18, not living in Thailand outside of refugee camps, does not meet meet or exceed the algorithm for the Hopkins Symptoms Checklist 25 (HSCL-25) depression subscale and/or the algorithm for the Harvard Trauma Questionnaire (HTQ) posttraumatic stress scale; active psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Waitlist-Control (Type: NO_INTERVENTION): Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
- Common Elements Treatment Approach (Type: EXPERIMENTAL): Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the Leva Incontinence System in Treating Bladder Incontinence.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Subjects must be female.~* Subjects must be capable of giving informed consent.~* Subjects should be at least 18 years of age and less than 89 years of age~* Subjects must have a diagnosis of or symptoms of predominant mild to moderate urinary incontinence based on the results of the completed urinary incontinence surveys.~Exclusion Criteria:~* Absence of a vagina.~* Positive drug or alcohol test at the screening visit.~* Post-menopausal defined as absence of a period for over 12 months.~* Pregnancy or being less than 12 months post-partum.~* Greater than three vaginal deliveries or prior operative delivery (e.g. use of vacuum, forceps or abdominal pressure).~* Symptoms of stage II or greater pelvic organ prolapse.~* BMI \>31 kg/m2.~* Diagnosis of any neurological disorder.~* Prior lower back or pelvic surgery, including prior surgery for stress urinary incontinence (SUI).~* Prior pelvic radiation.~* Current or recurrent vaginal infections (\>three per year).~* Painful bladder syndrome, active or chronic pelvic pain.~* Concurrent Pelvic Floor Muscle Exercises (PFME) under a supervised therapeutic plan of care.~* Previous supervised pelvic floor muscles rehabilitation in the past 12 months for the treatment for urinary incontinence or any other pelvic floor disorder.~* Currently taking medication to treat incontinence.~* Impaired cognitive function.~* Unable to tolerate use of the leva device.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Leva Arm (Type: EXPERIMENTAL): Subjects will use the leva device twice daily to perform pelvic floor muscle exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* Have a clinical diagnosis of SLE according to the American College of Rheumatology (ACR) classification criteria.~* Have active SLE disease.~* Have positive anti-nuclear antibody (ANA) test results.~* Are on a stable SLE treatment regimen.~* Females of childbearing age are willing to use appropriate contraception~Exclusion Criteria:~* Have received treatment with any B cell targeted therapy at any time.~* Have received a biologic investigational agent in the past year.~* Have received 3 or more courses of systemic corticosteroids in the past year.~* Have received intravenous (IV) cyclophosphamide within 180 days prior to Day 0.~* Have severe lupus kidney disease.~* Have active central nervous system (CNS) lupus.~* Have had a major organ transplant.~* Have significant unstable or uncontrolled acute or chronic diseases or conditions not due to SLE.~* Have a planned surgical procedure.~* Cancer within the last 5 years, except for adequately treated skin cancer, or carcinoma in situ of the uterine cervix.~* Have required management of acute or chronic infections in the past 60 days.~* Have current drug or alcohol abuse or dependence.~* Have a historically positive test, or test positive at screening for HIV, Hepatitis B, or Hepatitis C.~* Have an IgA deficiency.~* Have severe laboratory Abnormalities.~* Have had anaphylactic reaction to X-ray contrast agents or biologic agents.~* Suicidal behavior or ideation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab (Type: EXPERIMENTAL): 10mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibudilast and Withdrawal-Related Dysphoria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 21 and 45~2. Meet DSM-5 criteria for current Moderate-to-Severe AUD~3. Current Heavy Drinking (\> 14 drinks per week for men; \> 7 drinks per week for women), as indicated by self-reported drinking for the 30 days prior to screening~4. Have reliable internet access~Exclusion Criteria:~1. Currently receiving or seeking treatment for AUD\*~2. Past year DSM-5 diagnosis of any substance use disorder other than alcohol or nicotine~3. A lifetime diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder~4. Current use of drugs, other than marijuana, verified by a urine toxicology screen\*~5. Pregnant, nursing, or refusal to use reliable birth control (if female)\*~6. A medical condition that may interfere with safe participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension, diabetes, or AST, ALT, or GGT ≥ 3 times upper normal limit)~7. Self-reported recent (i.e. past 30 day) use of medications that are contraindicated with ibudilast\*~8. Non-removable ferromagnetic objects in body~9. Claustrophobia~10. Serious head injury or prolonged period of unconsciousness (\>30 minutes)~    * Participants who meet these criteria at any point during the course of the study (i.e. after randomization) will be withdrawn from the study for safety purposes.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ibudilast (Type: ACTIVE_COMPARATOR): 20mg BID Days 1-2 50mg BID Days 3-14
- Placebo (Type: PLACEBO_COMPARATOR): Matched to active

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Induction of Endogenous Antibiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-55 years of age~* duration of diarrhoea 0-4 days~* culture-confirmed Shigella spp (all Shigella spp) in stool on enrolment~Exclusion Criteria:~* who received antimicrobial treatment before attending the ICDDR,B hospital~* clinical symptoms of other concomitant infections (such as chronic respiratory infections, other concomitant gastrointestinal infections)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
- 2 (Type: PLACEBO_COMPARATOR): Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Clinical diagnosis of breast cancer,~* Clinical diagnosis of chemotherapy induced nausea and vomiting resistant to conventional therapy.~Exclusion Criteria:~* Clinical diagnosis of hypersensitivity to Sumac or Bunium Persicum,~* Clinical diagnosis of digestion disorders,~* Clinical diagnosis of non chemotherapy induced nausea and vomiting,~* Milk allergy,~* Clinical diagnosis of bleeding diathesis,~* Clinical diagnosis of non-breast cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- intervention (Type: ACTIVE_COMPARATOR): 2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
- control (Type: PLACEBO_COMPARATOR): 2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PMC Split Preparation for Colon Cleansing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult outpatients~* aged 18-85 yr~* undergoing elective colonoscopy~Exclusion Criteria:~* previous colon resection,~* ileus,~* intestinal obstruction,~* toxic megacolon,~* severe heart failure (NYHA Class III or IV),~* acute cardiovascular disease,~* uncontrolled arterial hypertension (systolic pressure \>170 mmHg, diastolic pressure \>100 mmHg),~* severe liver cirrhosis (Child-Pugh score C),~* renal failure (creatinine clearance\<30 mL/minute),~* ascites,~* phenylketonuria,~* glucose-6-phosphate dehydrogenase deficiency,~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Group A: standard regimen (Type: ACTIVE_COMPARATOR): Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
- Group B (Type: ACTIVE_COMPARATOR): Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged from 18 to 65 years.~* Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO classification) :~* Diffuse large B cell lymphoma.~* Adverse prognostic factors IPI\>1~* In Complete Remission, or partial response to first line treatment.~* Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP~* Chemo-sensitive disease~* PET Scan prior transplant~* Eligible for autologous stem cell transplantation~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* Histological transformation in diffuse large B cell lymphoma, any type of low grade lymphoma~* More than one line of treatment. Prior transplantation. Prior exposure to Zevalin~* Central nervous system or meningeal involvement by lymphoma.~* Contraindication to any drug contained in the chemotherapy regimen.~* Any serious active disease or co-morbid medical condition (according to the investigator's decision and information provided in the IDB).~* Poor renal function (creatinin level up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less than 100 G/l~* Large bone marrow irradiation more than 40percent.~* Bone marrow infiltration~* Lack of sufficient autologous hematopoietic stem cells for transplantation.~* Prior treatment with murine antibodies~* Known hypersensibility to murine antibodies or proteins~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient unable to give informed consent because of intellectual impairment.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete